Sector: Health Care
Director information for ULTRAGENYX PHARMACEUTICAL INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Amrit Ray, M.D. | Board member and advisor to various life science companies; Chairperson | 53 | [] | ["Research and Development Committee"] | 2026 |
| Amrit Ray, M.D., M.B.A. | Board member and advisor to various life science companies | 53 | ["Board member and advisor to life science companies", "Chief Patient Officer at Biohaven Ltd.", "Senior Adviser to Bain Capital Life Sciences", "Global President, Head of R&D and Medical, for Pfizer Essential Health", "Senior Vice President, External Affairs (Science and Medicine) at Johnson & Johnson", "Senior Vice President, Chief Medical Officer of Janssen", "Senior Vice President, Chief Safety Officer", "Trustee at the Board of the Hastings Center for Bioethics", "Visiting Professor of Practice, Faculty of Medical Sciences at Newcastle University", "Holds a B.S., with Honours, in Immunology", "Holds an M.D. (M.B., Ch.B.) from the University of Edinburgh", "Holds an M.B.A. from the Tuck School of Business at Dartmouth College"] | ["1"] | 2026 |
| Corsee D. Sanders, Ph.D. | Board member and advisor to various life science companies; Board member and adviser to various life science companies | 69 | ["Board member and advisor to life science companies", "Executive Vice President at Juno Therapeutics, Inc.", "Strategic advisor to the Chief Medical Officer of Celgene Corporation", "Transition Advisor to the Clinical Development team at BMS", "Positions of increasing responsibility at Genentech/Roche", "Senior Vice President, Global Head of Clinical Operations and Industry Collaboration at Genentech/Roche", "B.S. and M.S. in Statistics from the University of the Philippines", "M.A. and Ph.D. in Statistics from the Wharton Doctoral Program at the University of Pennsylvania"] | ["Research and Development Committee"] | 2026 |
| Daniel G. Welch | Board member and advisor to various life science companies; Independent Chairman | 68 | ["Advisor to various life science companies", "Chairman on the boards of Structure Therapeutics, Inc. and Prothena Corporation plc", "Executive Partner at Sofinnova Ventures", "Chairman, Chief Executive Officer, and President of InterMune, Inc.", "Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc.", "President of the pharmaceutical division of Elan Corporation, plc", "Chairman of the board of directors of Nuvation Bio", "Director on the boards of Intercept Pharmaceuticals, Inc and Seagan Inc.", "B.S. from the University of Miami", "M.B.A. from the University of North Carolina", "Strong operating executive with operational and strategic expertise in the global pharmaceutical market"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| Deborah Dunsire, M.D. | Board member and advisor to various life science companies | 63 | ["President and Chief Executive Officer of H. Lundbeck A/S", "President and Chief Executive Officer and director of Xtuit Pharmaceuticals, Inc.", "President and Chief Executive Officer and director of FORUM Pharmaceuticals Inc.", "Corporate officer at Takeda Pharmaceutical Company Limited", "Director at Takeda Pharmaceutical Company Limited", "President and Chief Executive Officer and director of Millennium Pharmaceuticals, Inc.", "President and Chief Executive Officer of Millennium: The Takeda Oncology Company", "Various roles at Novartis Pharma AG"] | ["Research and Development Committee"] | 2026 |
| Emil D. Kakkis, M.D., Ph.D. | Founder, President and CEO, Ultragenyx; President and Chief Executive Officer, Director | 65 | ["Founder and Chief Executive Officer of Ultragenyx", "Former interim principal financial officer", "Former Chief Medical Officer at BioMarin Pharmaceutical Inc.", "Founder of EveryLife Foundation for Rare Diseases", "Board certified in Medical Genetics and Pediatrics", "B.A. in Biology from Pomona College", "Combined M.D. and Ph.D. degrees from UCLA School of Medicine"] | ["Research and Development Committee"] | 2026 |
| Matthew K. Fust | Board member and advisor to various life science companies | 61 | ["Board member and advisor to life science companies", "Independent director with experience in publicly traded biopharmaceutical companies", "Former Executive Vice President of Onyx Pharmaceuticals, Inc.", "Former Chief Financial Officer at Jazz Pharmaceuticals, Inc.", "Former Chief Financial Officer at Perlegen Sciences, Inc.", "Former Chief Financial Officer at ALZA Corporation", "Experience as a manager in the healthcare strategy practice at Andersen Consulting", "B.A. in Accounting from the University of Minnesota", "M.B.A. from the Stanford Graduate School of Business"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| Michael Narachi | Board member and advisor to various life science companies | 66 | ["President and Chief Executive Officer of CODA Biotherapeutics", "President, Chief Executive Officer and director of Orexigen Therapeutics", "Chairman, Chief Executive Officer, and President of Ren Pharmaceuticals", "Vice President of Amgen Inc.", "General Manager of Amgen\u2019s Anemia Business", "member of the board of directors of BIO", "member of the board of directors of PhRMA", "chairman of the board of directors of Celladon Corporation", "director of AMAG Pharmaceuticals"] | [] | 2026 |
| Shehnaaz Suliman, M.D. | Chief Executive Officer of ReCode Therapeutics; Chairperson | 54 | [] | ["Nominating and Corporate Governance Committee"] | 2026 |
| Shehnaaz Suliman, M.D., M.Phil., M.B.A | Chief Executive Officer of ReCode Therapeutics | 54 | ["Chief Executive Officer of ReCode Therapeutics", "President and Chief Operating Officer of Alector, Inc.", "Senior Vice President, Corporate Development and Strategy of Theravance Biopharma, Inc.", "Group Leader and Project Team Leader at Genentech, Inc.", "Vice President and Global Therapeutic Head, Roche Partnering", "management roles at Gilead Sciences, Inc.", "investment banker with Lehman Brothers and Petkevich & Partners", "member of the board of directors of 10X Genomics, Inc.", "M.D. from the University of Cape Town Medical School", "M.B.A, with distinction, and M.Phil. in Development Studies from Oxford University"] | [] | 2026 |
